Get the latest news from Nation Next in your inbox.
A study published in bioRxiv by Indian Council of Medical Research (ICMR) has stated that Bharat Biotech's COVID vaccine Covaxin (BBV152) against the Delta Plus (AY.1) variant of coronavirus. The study is pre-print and has not been reviewed.
The study stated: "Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of COVID-19 naive individuals full doses of BBV152 vaccine, COVID-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3."
The study stated that the SARS-CoV-2 Variant B.1.617.2 (Delta) variant with its high transmissibility is believed to be responsible for the second wave in India. Subsequently, Delta has further mutated to Delta AY.1, AY.2, and AY.3. Of these, AY.1 variant was first detected in India in April 2021 and subsequently from 20 other countries as well.
Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomised, multicentre, phase 3 clinical trial.